A study conducted in 2022 revealed that around 19.83 million Americans were affected by some form of age-related macular degeneration (AMD). Out of these, around 1.49 million people were affected by late-stage AMD. The prevalence of developing the condition increases with age. It rises from 2% (for people aged 40 to 44 years) to 46.6% (for people aged above 85). As the global geriatric population is growing, the demand for high-efficacy macular degeneration drugs is on the rise. This has prompted major healthcare institutions to develop new drugs, resulting in an increased number of drugs in the pipeline.
The Macular Degeneration Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into macular degeneration therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for macular degeneration. The macular degeneration report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The macular degeneration pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with macular degeneration treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to macular degeneration.
Age-related macular degeneration (AMD) is a condition which damages a part of the retina (macula), leading to loss of central vision. It is commonly divided into two categories, namely, dry AMD and wet AMD. Dry age-related macular degeneration involves thinning of the macula with age and formation of drusen (small protein clumps). It is more common as compared to wet AMD. The American Academy of Ophthalmology reports that 8 out of 10 people are affected by dry AMD. Although less common, wet AMD is considered to be more serious as vision loss is faster in comparison to dry AMD. It involves the growth of new and abnormal blood vessels under the retina. These blood vessels may leak and scar the macula significantly.
Macular degeneration treatment involves the use of anti-VEGF therapies, which work by inhibiting abnormal vessel growth and decreasing the chance of fluid leakage. Photodynamic therapy and laser photocoagulation can also be used based on patient profiles. In 2023, two new drugs Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) received the U.S. FDA’s approval for geographic atrophy (a late stage of dry AMD) treatment. These intravenous drugs slowed disease progression by about 14% to 20%.
For years, patients have been limited to using AREDS2 vitamins for treating intermediate stages of dry AMD. However, the approval of new drugs elevates hope for both patients and healthcare professionals to manage the condition more efficiently.
This section of the report covers the analysis of macular degeneration drug candidates based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s macular degeneration report assessment covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials conducted, with over 550 macular degeneration emerging drugs undergoing clinical development.
The drug class categories covered under macular degeneration pipeline analysis include anti-VEGF (vascular endothelial growth factor) agents, anti-inflammatory agents (corticosteroids), complement inhibitors and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials. According to EMR analysis, gene therapy, stem cell therapy and other photodynamic therapies are under investigation and likely to impact the drug class landscape significantly in coming years.
The EMR report for the macular degeneration drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed macular degeneration therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in macular degeneration clinical trials:
This investigational gene therapy is currently under phase 2 clinical trials of a program initiated by The Department of Ophthalmology at Columbia University Irving Medical Center. It acts on the complement factor I (CFI) protein that inhibits the immune system from attacking the retina cells. This intravenous drug intended to treat geographic atrophy secondary to dry age-related macular degeneration has also received Fast-Track Designation from the United States FDA.
Developed by Adverum Biotechnologies Inc., this macular degeneration drug candidate showed efficacy in over 90% of the subjects in the LUNA Phase 2 trial. This trial involves 60 patients with wet AMD and is divided across two dose cohorts 2E11 and 6E10 vg/eye. Both doses involved showed visual as well as anatomic outcomes, signifying its efficacy.
4D Molecular Therapeutics’ wet AMD drug candidate 4D-150 showed positive outcomes in Phase 2 PRISM clinical trial. This trial evaluated the safety, durability, and suitability of the drug. The company aims to present the drug for Phase 3 and apply for FDA RMAT and EMA PRIME designations as well.
Sponsored by Cognition Therapeutics, this drug is under evaluation to treat late-stage dry AMD. CT-1812 is a small-molecule oral medication that has the potential to cross the blood-retinal barrier and reach the back of the retina without injection intervention. The drug will be evaluated on 246 patients as a part of the Phase 2 MAGNIFY study.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Macular Degeneration Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for macular degeneration. It provides the necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities provided by the macular degeneration drug report.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share